STK11 and non-small cell lung carcinoma: Almost 40% of LCNECs have molecular alterations often identified in non-small cell lung cancer (STK11, and KEAP1 mutations) with high expression of ASCL1 and neuroendocrine markers (defined as type I LCNEC) [23,24].